key: cord-1042259-kyx062by
authors: Ragan, Izabela K; Hartson, Lindsay M; Dutt, Taru S; Obregon-Henao, Andres; Maison, Rachel M; Gordy, Paul; Fox, Amy; Karger, Burton R; Cross, Shaun T; Kapuscinski, Marylee L; Cooper, Sarah K; Podell, Brendan K; Stenglein, Mark D; Bowen, Richard A; Henao-Tamayo, Marcela; Goodrich, Raymond P
title: A whole virion vaccine for COVID-19 produced via a novel inactivation method: results from animal challenge model studies
date: 2020-11-13
journal: bioRxiv
DOI: 10.1101/2020.11.13.381335
sha: 9d53cf7c29aebbf366bfe264a4f27fc1f75cc089
doc_id: 1042259
cord_uid: kyx062by

The COVID-19 pandemic has generated intense interest in the rapid development and evaluation of vaccine candidates for this disease and other emerging diseases. Several novel methods for preparing vaccine candidates are currently undergoing clinical evaluation in response to the urgent need to prevent the spread of COVID-19. In many cases, these methods rely on new approaches for vaccine production and immune stimulation. We report on the use of a novel method (SolaVAX™) for production of an inactivated vaccine candidate and the testing of that candidate in a hamster animal model for its ability to prevent infection upon challenge with SARS-CoV-2 virus. The studies employed in this work included an evaluation of the levels of neutralizing antibody produced post-vaccination, levels of specific antibody sub-types to RBD and spike protein that were generated, evaluation of viral shedding post-challenge, flow cytometric and single cell sequencing data on cellular fractions and histopathological evaluation of tissues post-challenge. The results from this study provide insight into the immunological responses occurring as a result of vaccination with the proposed vaccine candidate and the impact that adjuvant formulations, specifically developed to promote Th1 type immune responses, have on vaccine efficacy and protection against infection following challenge with live SARS-CoV-2. This data may have utility in the development of effective vaccine candidates broadly. Furthermore, the results suggest that preparation of a whole virion vaccine for COVID-19 using this specific photochemical method may have utility in the preparation of one such vaccine candidate. Author Summary We have developed a vaccine for COVID-19 which is prepared by a novel method for inactivation of a whole virion particle and tested it in a hamster animal model for its ability to protect against SARS-CoV-2 infection.

Coronavirus disease 2019 , caused by the virus SARS-CoV-2, continues to 56 spread globally leading to significant impacts on public health [1] . As of August 2020, over 29 57 million total cases have been confirmed and over 900,000 deaths have been reported globally [2] . 58 SARS-CoV-2, or Severe Acute Respiratory Syndrome coronavirus 2, causes primarily respiratory 59 infections in humans and is related to other coronaviruses like Middle East Respiratory Syndrome 60 Coronavirus (MERS-CoV) and SARS-CoV [3] . Not only has SARS-CoV-2 caused a public health 61 emergency on a global scale but it continues to have major social, cultural, and economic impacts. 62 Vaccination is the most effective countermeasure for mitigating pandemics and has proven 63 effective against viral pathogens such as smallpox and polio. 64 The emergence of SARS-CoV-2 in human populations spurred the scientific community The use of these vaccine production methods is predicated on the ability to achieve 76 inactivation of the pathogen's ability to replicate while preserving the antigenic protein structural 77 potency and integrity [7] . Methods for producing such candidates require the use of chemicals 78 such as beta-propiolactone, ethylenimine, formalin as well as the use of physical inactivation 79 methods such as gamma irradiation, high energy UV light (UVC) and heat inactivation. These 80 methods work primarily by chemically modifying protein and nucleic acid structures of pathogens 81 through covalent modification, crosslinking, oxidation and structural alteration, rendering the 82 treated agents unable to infect target cells or replicate in vivo. The key to success with such 83 approaches resides in the ability to balance the alterations required for inactivation with the 84 preservation of antigen epitopes similar to the native agent that are required to stimulate immune 85 response when administered to a host. A method which can successfully prevent pathogen 86 replication without inducing alterations to antigen targets is ideal. Candidates produced by such a 87 method would possess the native protein structures that are as close to natural structures in the 88 intact pathogen as possible without the ability to induce disease. 89 We report a novel method (SolaVAX TM ) to produce a candidate vaccine for COVID-19. 90 This method employs the use of a photochemical (riboflavin or vitamin B2) in combination with 91 UV light in the UVA and UVB wavelength regions to carry out specific nucleic acid alterations 92 through electron transfer chemistry-based processes [8] . The method was originally developed for 93 the treatment of blood products to prevent transfusion transmitted diseases [9] and has been in 94 routine clinical use for prevention of transfusion transmitted viral, bacterial and parasitic diseases 95 since 2008 [10] . The process utilizes a well-established and demonstrated capability of riboflavin 96 and UV light to modify nucleic acid structure primarily through modification of guanine bases in 97 a non-oxygen dependent process utilizing the natural electron donor-acceptor chemistry associated 98 with guanine and riboflavin, respectively [11] . 99 The specificity of the riboflavin photochemistry used in this process avoids the alkylation, 100 crosslinking and covalent modifications that are associated with other chemical and photochemical 101 mechanisms of pathogen inactivation [12] . The process allows for retention of plasma and cell-102 bound protein structure post treatment to an extent that such products may still be efficacious in 103 functional utilization for transfusion support of patients [13, 14] . Unlike the standard chemical 104 agents such as beta-propiolactone and ethyleneimine derivatives that are routinely used for 105 inactivated vaccine production, the photochemical used in this approach (riboflavin) has a well- 106 established safety toxicology profile, is non-mutagenic and non-carcinogenic and poses little to no 107 toxicity or disposal risk to facility personnel or the environment. This safety profile has been 108 documented extensively in pre-clinical and clinical programs in human subjects [15] . 109 For this work, we hypothesized that the use of these methods for production of an 110 inactivated virus of SARS-CoV-2 could have several advantages. These included the ability to 111 utilize existing equipment, reagents and disposables that are in routine use for treatment of blood 112 products to produce an inactivated vaccine preparation when using purified viral stocks of the 113 target virus, e.g., SARS-CoV-2 in this particular application [16] . We hypothesized that the 114 selectivity of the chemistry applied in this process would generate a vaccine candidate that was 115 fully attenuated with regard to replication capabilities while maintaining viral protein structural 116 integrity as close to the native virus as possible. We further hypothesized that such a candidate 117 produced by this method would be able to induce a potent immune response with relatively low 118 doses of immunogen and thus provide protective immunity against live virus challenge. 119 Our approach to evaluate this candidate utilized both in vitro analysis and animal models 120 (Syrian Golden Hamsters), developed in house and shown to be susceptible to disease in the upper 121 and lower respiratory tract following exposure to live SARS-CoV-2 virus administered 122 intranasally. Animals exposed in this way were demonstrated to produce and shed virus 123 extensively at days 3-7 post-exposure. Our damage to G bases in viral RNA in the form of elevated frequencies of G to U and G to C 152 mismatches (Fig. 1B) . These lesions would result from the misincorporation of an A or a G 153 opposite an oxidized G during reverse transcription. The frequency of G to U mutations was 2.3x 154 higher in photoinactivated RNA than in untreated RNA (0.0021 vs. 0.0009), and this ratio was 155 1.8x for G to C mutations (0.0012 vs 0.0007; Fig. 1C ). Given the combined mutation frequency of 156 ~0.0033 and 5,863 G bases in the SARS-CoV-2 USA-WA1 genome, an average of 19.6 G bases third group (CpG) received inactivated vaccine with CpG 1018 adjuvant, and the fourth group 165 (ODN) received inactivated vaccine with ODN1668 adjuvant. Within each group hamsters were 166 divided in 2 subgroups that were vaccinated either by subcutaneous (SC) or by intramuscular (IM) 167 injection (Fig.1A) . None of the hamsters showed any clinical adverse reactions to the vaccination. 168 Moreover, after viral challenge all hamsters were clinically normal. CoV-2 infection. 180 In addition to oral-pharyngeal swabs, necropsies were performed and tissues collected at 3 181 dpi to determine vaccine efficacy after live virus challenge. These tissues were specific to 182 respiratory tract and included the right cranial lung lobe, right caudal lung lobe, trachea, and nasal 183 turbinates Beginning with nasal turbinates (Fig. 2C) , these tissue samples revealed high viral titers 184 for all hamsters regardless of vaccination status. This was expected due to the route of live virus 185 inoculation, yet the Control group had higher viral titers compared to the vaccinated groups. 186 Moreover, there was a significant decrease in viral titers in the CpG group within the IM subgroup 187 demonstrating that the IM injection of SolaVAX+CpG 1018 offered the best protection against 188 viral replication in nasal turbinates. 189 Trachea was also evaluated to see if vaccination would protect the lower airway against 190 SARS-CoV-2 infections (Fig. 2D) . The viral titers are less than what was observed in the turbinates 191 and support what has been seen in previous experimental hamster infections with SARS-CoV-2. was an increase of antibody response in all but one of the vaccinated hamsters ranging from 1:40-223 serum from naïve hamsters was used as a negative control. A strong IgG response against the three 233 viral proteins was detected in infected hamsters previously vaccinated with SolaVAX. In contrast, 234 IgG levels against viral proteins were below the detection limit in hamsters in the Control group. 235 The following trend was observed for all vaccinated hamsters regardless of vaccination route: a) 236 Titers against the S1 protein and RBD subunit were higher than against the S2 protein; b) IgG 237 levels were greater in infected hamsters vaccinated with SvX, followed by ODN and CpG groups. (Table S2 ). The immunological response to SARS-CoV-2 infection in non-vaccinated hamsters 302 relied on innate cells such as inflammatory monocytes, neutrophils, plasmacytoid dendritic cells 303 and natural killer T cells. In contrast, hamsters vaccinated with SvX, particularly when formulated 304 with CpG, had a higher frequency of lymphocytes from the adaptive immune response. 305 Specifically, both activated CD4 T cells and cytotoxic CD8 T cells highly expressing XCL1, were 306 increased in vaccinated hamsters. Interestingly, a specific subset of B cells that does not express 307 IgJ are significantly increased in CpG group. 308 The average log-fold change gene expression (avglogFC) was compared between different 309 clusters and groups (Fig.7) . In Control hamsters, genes associated with inflammation (NLRP3, IL-310 1B, CXCL10, CCL4, CCL8, IFI16), were one to two-fold higher in myeloid cells. In contrast, anti- The production of neutralizing antibodies was determined by plaque reduction 513 neutralization test. Briefly, serum was first heat-inactivated for 30 minutes at 56°C in a waterbath. 514 Then serum samples were diluted two-fold in BA-1 media starting at a 1:5 dilution on a 96-well 515 plate. An equal volume of SARS-CoV-2 virus (isolate USA-WA1/2020) was added to the serum 516 dilutions and the sample-virus mixture was gently mixed. The plates were incubated for 1-hour at 517 37 o C. Following incubation, serum-virus mixtures were plated onto Vero E6 plates as described 518 for virus plaque assays. Antibody titers were recorded as the reciprocal of the highest dilution in 519 which >90% of virus was neutralized. All hamsters were tested for the presence of antibodies 520 against SARS-CoV-2 prior to vaccination. (Table S3) Single cell RNA sequencing 593 Lungs cells were prepared as described above, filtered, washed and resuspended in PBS + 594 0.4% BSA. Cells were counted using a hemocytometer, and ~12,000 cells were added to the 10x 595 Genomics chromium Next GEM Chip for a target recovery of 8,000 cells. GEMs were placed in a 596 thermal cycler and cDNA purified using Dynabeads. cDNA amplification was done using 10x 597 Genomics single cell v3' chemistry as per the manufacturer's recommendations. The amplification 598 PCR was set at 11 cycles and to eliminate any traces of primer-dimers, the PCR amplified cDNA 599 product was purified using 0.6x SPRI beads (Beckman Coulter) before using the DNA for 600 sequencing library preparation. Quality and quantity of cDNA was determined via Agilent 601 TapeStation analysis using a HS-D5000 screen tape (Fig. S3) . Twenty-five percent (25%) of the 602 total cDNA amount was carried forward to generate barcoded sequencing libraries with 10 cycles 603 of Sample Index PCR in 35-mL reaction volume (Fig. S4 ). Libraries were then pooled at equal 604 molar concentration (Fig. S5 ) and sequenced on an Illumina NextSeq 500 sequencer to obtain a 605 total of 941M read pairs (Illumina). An average of 78M read pairs per sample were generated with 606 a standard deviation of 10.7M read pairs. Low-quality cells with <200 genes/cell and cells that 607 express mitochondrial genes in >15% of their total gene expression were excluded. Gene 608 expression in each group was normalized based on the total read count and log transformed. TCF4, FSCN1, CD83 plasmacytoid dendritic cells [33, 34] CD3D, CD8A, GZMA, GZMB, NKG7, CD44 Cytotoxic CD8 T cells [33] [34] [35] CD3D, CD8A, GZMA, NKG7, CD44, XCL Cytotoxic CD8 T cells, XCL hi [33] [34] [35] CD3D, CD4, CD44, CD62L, CD38 Central memory CD4+ T cells [33, 34] CD3D, CD4, CD44, TNFRSF4 Activated CD4+ T cells [33] CD3D, GZMA, GZMK, TNFRSF NK cells [33, 35] CD79B, CD74, H2-Aa, IGJ, IGHM B cells IGJ hi [33, 36] CD79B, CD74, H2-Aa B cells [33, 36] SFTPC, SFTPB Type -II alveolar cells [33] SFTPC, SOX4 Epithelial progenitor cells [33] using Seurat pipeline. These clusters were classified into different cell types based on specific markers cited in literatures. 

A Deadly Coronavirus Was Inevitable. Why was No One Ready? 641

Clinical Course and Risk Factors for 645

Mortality of Adult Inpatients with COVID-19 in Wuhan, China: a Retrospective Cohort Study

The Long Road Toward COVID-19 Herd 648 Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

New Vaccine Technologies to Combat Outbreak 651 Situations

Vero Cell Technology for Rapid 653

Development of Inactivated Whole Virus Vaccines for Emerging Viral Diseases. Expert Rev 654 Vaccines

Inactivated Virus Vaccines from Chemistry to 656

Prophylaxis: Merits, Risks and Challenges

Chemical and Biological Mechanisms 658 of Pathogen Reduction Technologies

Inactivation of Selected Viruses and Bacteria in Platelet Concentrates using Riboflavin and 661

Improving the Safety of 663

Whole Blood-derived Transfusion Products with a Riboflavin-Based Pathogen Reduction 664 Technology

photosensitized Inactivation of Lambda Phage

Riboflavin and UV-668 light Based Pathogen Reduction: Extent and Consequence of DNA Damage at the Molecular 669

Hemostatic Efficacy of Pathogen-inactivated vs Untreated Platelets: a 672

Plasmodium inactivation in Whole Blood on the Incidence of Blood Transfusion-transmitted 675

Malaria in Endemic Regions: the African investigation of the Mirasol System

Toxicity Testing of a Novel 678

Riboflavin-based Technology for Pathogen Reduction and White Blood Cell Inactivation

Antiviral and Antibacterial Properties of Riboflavin and Light: Application to Blood Safety 682 and Transfusion Medicine

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on 686 Challenge with the SARS Virus

The Potential of 1018 ISS Adjuvant in 688

Identification of Common Deletions in 690 the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2

SARS-Coronavirus-2 Replication in Vero E6 Cells: Replication Kinetics, Rapid Adaptation 694 and Cytopathology

Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease

Oxidative Base Damage in RNA Detected by Reverse 699

Antibody Responses to SARS-CoV-2 in Convalescent Individuals

A Novel Cancer Immunotherapy 703

Utilizing Autologous Tumour Tissue

Pilot Acute Safety Evaluation of 705

26. MacLennan CA. Vaccines for Low-income Countries

Fast Gapped-read Alignment with Bowtie 2

Modeling the Evolution of SIV Sooty Mangabey Progenitor Virus towards HIV-2 using 711

Engineering: A Pipeline for Flow Cytometry Analysis to Uncover Immune Populations and 714

Host-Viral Infection Maps Reveal 718 Signatures of Severe COVID-19 Patients

Identifies Unique Inflammatory Airspace Macrophage Subsets

seq Reveals New Types of Human Blood Dendritic Cells, Monocytes, and Progenitors

Early Unipotent Neutrophil Progenitor with Pro-Tumoral Activity in Mouse and Human Bone 727

Influenza Highlights the Role of Type I Interferons in Development of Severe COVID-19

Transcriptomics of Human T Cells Reveals Tissue and Activation Signatures in Health and 733 Disease

Human Germinal Center Transcriptional Programs are De-synchronized in B Cell Lymphoma

T Cells are not Required for Pathogenesis in the Syrian Hamster 738 Model of Hantavirus Pulmonary Syndrome

The Adaptive Immune 740 Response does not Influence Hantavirus Disease or Persistence in the Syrian Hamster

Tumoural Activity and Toxicity of the Three Adv-TKs